Rheumatoid arthritis and the evolution of therapy: from symptomatic to bench-to-bedside biological drugs

Author： Lukas Cédric   Combe Bernard   Morel Jacques  

Publisher： Future Medicine

ISSN： 1746-0816

Source： Future Rheumatology, Vol.2, Iss.2, 2007-04, pp. : 143-152

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tocilizumab: a new form of biological therapy for rheumatoid arthritis

By Balint Geza P   Balint Peter V  

Future Rheumatology, Vol. 2, Iss. 4, 2007-08 ,pp. : 361-371

Future Medicine

Access to resources Recommend Favorite

Molecular Targeted Therapy for Hepatocellular Carcinoma: Bench to Bedside

By  

Digestive Diseases, Vol. 29, Iss. 3, 2011-08 ,pp. : 273-277

Karger

Access to resources Recommend Favorite

Gene therapy for rheumatoid arthritis

By Reinhardt Adam   Hirsch Raphael  

Future Rheumatology, Vol. 2, Iss. 4, 2007-08 ,pp. : 403-413

Future Medicine

Access to resources Recommend Favorite

A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology

By Takamura Akito  

Modern Rheumatology, Vol. 23, Iss. 2, 2013-03 ,pp. : 297-303

Springer Publishing Company

Access to resources Recommend Favorite

From bedside to bench and back: the tale of MODY

By Sussel L.   Eisenbarth G.S.  

Trends in Endocrinology and Metabolism, Vol. 12, Iss. 6, 2001-08 ,pp. : 277-278

Elsevier

Access to resources Recommend Favorite